Baxfendy Hypertension Treatment: FDA Approves F...

By HEOR Staff Writer

May 22, 2026

Baxfendy hypertension treatment received US Food and Drug Administration approval as the first aldosterone synthase inhibitor for adults with hypertension not adequately controlled on other antihypertensive medications. AstraZeneca’s Baxfendy (bax...
TrumpRx.gov Expansion: Enhancing Medication Price Transparency and Competition
PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment
Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvan...
Pharmaceutical Onshoring Agreements: Navigating Tariff Relief and National Se...
Dynamic Risk Stratification in Thromboembolism Prevention for Cancer Patients
Merck Oncology Advancements Highlight Long-Term Data and Pipeline Progress at...
Johnson & Johnson Advances Neuropsychiatry Treatment Innovations at APA ...
Breakthrough in Biocatalysis: Advancing Oral PCSK9 Inhibitors
FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases
MFN Drug Pricing Savings: Projected $593 Billion in U.S. Healthcare Savings O...
Navigating the Challenges of Patient-Centered AI Systems in Postpartum Depres...
JNJ-4804 IBD Therapy Proves Effective for Refractory Inflammatory Bowel Disease